.jpeg)
2026-09-29 06:25:46
Pemigatinib is an oral FGFR1/2/3 inhibitor for advanced FGFR2 fusion/rearrangement cholangiocarcinoma and selected FGFR1-rearranged myeloid/lymphoid neoplasms. Cholangiocarcinoma uses 13.5mg once daily, 14 days on and 7 days off; FIGHT-302 and FIGHT-202 support sequencing decisions, with serum phosphate and OCT ophthalmology monitoring.
2026-09-28 04:14:55
Dabrafenib (Tafinlar) is an oral BRAF inhibitor active only in tumors with a BRAF V600E/K mutation. This guide covers its mechanism, FDA-approved indications, adult and pediatric dosing, the evidence for combining it with trametinib, and practical management of adverse reactions.
2026-09-22 08:14:01
How binimetinib adds MEK1/2 blockade to encorafenib in BRAF V600E/K unresectable or metastatic melanoma, covering mechanism, response, resistance and monitoring.
2026-09-17 02:55:47
Adagrasib is an oral irreversible KRAS G12C inhibitor. NSCLC standard dosing is 600mg twice daily; manage diarrhea, nausea, hepatotoxicity, QTc prolongation, and ILD. Colorectal use with cetuximab is under re-evaluation after KRYSTAL-10 missed PFS/OS endpoints.
2026-09-14 03:36:10
Ceritinib is an oral ALK tyrosine kinase inhibitor for validated ALK-rearranged locally advanced or metastatic non-small cell lung cancer. Usual 450mg once daily with food, with active management of diarrhea, hepatotoxicity, hyperglycemia, and QT prolongation.
2026-09-14 03:09:28
Enzalutamide commonly causes fatigue, musculoskeletal pain, dizziness, and hot flashes, with attention also needed for hypertension, falls, fractures, seizure, PRES, and ischemic heart disease. This guide covers tiered management and red-flag symptoms.
2026-09-10 03:33:16
Tamoxifen is a long-established endocrine therapy for breast cancer. Long-term use requires awareness of venous thromboembolism and endometrial abnormalities. This article outlines key adverse effects and at-risk populations.
2026-09-10 03:00:52
Worsening symptoms or declining cardiac function during acoramidis treatment for ATTR-CM should not be directly labeled as drug resistance. This article explains the mechanism, proper assessment methods, and dosing compliance.
2026-09-10 02:56:36
Lorlatinib has only one formal contraindication (prohibited co-administration with strong CYP3A inducers), but six major safety risks require close attention, including CNS effects, dyslipidemia, and interstitial lung disease.
2026-09-09 07:04:37
Dacomitinib is a second-generation irreversible EGFR TKI for first-line treatment of metastatic NSCLC with EGFR exon 19 deletion or L858R mutation. This article details dosing, switching strategies, comparison with osimertinib, and adverse event management.
2026-09-09 06:37:44
Abemaciclib is a CDK4/6 inhibitor for hormone receptor-positive, HER2-negative breast cancer. This article explains its mechanism, synergy with endocrine therapy, efficacy differences between mono and combination, and precautions when switching from other CDK4/6 inhibitors.
2026-09-08 05:30:58
Cemiplimab is a PD-1 immune checkpoint inhibitor that blocks PD-1 from binding to PD-L1/PD-L2, releasing T-cell suppression and enabling immune attack on tumors. This article explains its mechanism and clinical indication screening.
